Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Correction: Activation of Notch Signaling Is Required for Cholangiocarcinoma Progression and Is Enhanced by Inactivation of p53 In Vivo.

El Khatib M, Bozko P, Palagani V, Malek NP, Wilkens L, Plentz RR.

PLoS One. 2018 Nov 1;13(11):e0206953. doi: 10.1371/journal.pone.0206953. eCollection 2018.

2.

Silencing of Kangai 1 C-terminal interacting tetraspanin suppresses progression of cholangiocarcinoma.

Bui KC, Barat S, Chen X, Bozko P, Scholta T, Nguyen MLT, Bhuria V, Xing J, Nguyen LT, Le HS, Velavan TP, Sipos B, Wilkens L, Malek NP, Plentz RR.

Exp Cell Res. 2018 Mar 1;364(1):59-67. doi: 10.1016/j.yexcr.2018.01.028. Epub 2018 Jan 31.

PMID:
29366806
3.

Editorial: DNA Damage as a Strategy for Anticancer Chemotherapy.

Bozko M, Bozko A, Scholta T, Malek NP, Bozko P.

Curr Med Chem. 2017;24(15):1487. doi: 10.2174/092986732415170630115722.

PMID:
28728539
4.

Therapeutic effects of Argyrin F in pancreatic adenocarcinoma.

Chen X, Bui KC, Barat S, Thi Nguyen ML, Bozko P, Sipos B, Kalesse M, Malek NP, Plentz RR.

Cancer Lett. 2017 Jul 28;399:20-28. doi: 10.1016/j.canlet.2017.04.003. Epub 2017 Apr 10.

PMID:
28408354
5.

Gamma-Secretase Inhibitor IX (GSI) Impairs Concomitant Activation of Notch and Wnt-Beta-Catenin Pathways in CD44+ Gastric Cancer Stem Cells.

Barat S, Chen X, Cuong Bui K, Bozko P, Götze J, Christgen M, Krech T, Malek NP, Plentz RR.

Stem Cells Transl Med. 2017 Mar;6(3):819-829. doi: 10.1002/sctm.16-0335. Epub 2017 Feb 3.

6.

Editorial (Thematic Issue: Pathogenetic Mechanisms of CLL - A Target in Therapy).

Bozko M, Podhorecka M, Macheta A, Bozko A, Malek NP, Bozko P.

Curr Cancer Drug Targets. 2016;16(8):651. No abstract available.

PMID:
27758697
7.

Deregulation of Apoptosis - Is it Still an Important Issue in Pathogenesis of Chronic Lymphocytic Leukemia?

Podhorecka M, Macheta A, Bozko M, Bozko A, Malek NP, Bozko P.

Curr Cancer Drug Targets. 2016;16(8):652-658. Review.

PMID:
27117115
8.

Correction: Capsaicin Treatment Attenuates Cholangiocarcinoma Carcinogenesis.

Wutka A, Palagani V, Barat S, Chen X, El Khatib M, Götze J, Belahmer H, Zender S, Bozko P, Malek NP, Plentz RR.

PLoS One. 2016 Sep 20;11(9):e0162673. doi: 10.1371/journal.pone.0162673. eCollection 2016.

9.

A Critical Role for Notch Signaling in the Formation of Cholangiocellular Carcinomas.

Zender S, Nickeleit I, Wuestefeld T, Sörensen I, Dauch D, Bozko P, El-Khatib M, Geffers R, Bektas H, Manns MP, Gossler A, Wilkens L, Plentz R, Zender L, Malek NP.

Cancer Cell. 2016 Aug 8;30(2):353-356. doi: 10.1016/j.ccell.2016.07.005. Epub 2016 Aug 8. No abstract available.

10.

A MYC-aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer.

Dauch D, Rudalska R, Cossa G, Nault JC, Kang TW, Wuestefeld T, Hohmeyer A, Imbeaud S, Yevsa T, Hoenicke L, Pantsar T, Bozko P, Malek NP, Longerich T, Laufer S, Poso A, Zucman-Rossi J, Eilers M, Zender L.

Nat Med. 2016 Jul;22(7):744-53. doi: 10.1038/nm.4107. Epub 2016 May 23.

PMID:
27213815
11.

Comparative study of antitumor effects of bromelain and papain in human cholangiocarcinoma cell lines.

Müller A, Barat S, Chen X, Bui KC, Bozko P, Malek NP, Plentz RR.

Int J Oncol. 2016 May;48(5):2025-34. doi: 10.3892/ijo.2016.3411. Epub 2016 Mar 1.

PMID:
26935541
12.

Targeting c-MET by LY2801653 for treatment of cholangiocarcinoma.

Barat S, Bozko P, Chen X, Scholta T, Hanert F, Götze J, Malek NP, Wilkens L, Plentz RR.

Mol Carcinog. 2016 Dec;55(12):2037-2050. doi: 10.1002/mc.22449. Epub 2016 Jan 12.

PMID:
26757360
13.

Helicobacter pylori promotes eukaryotic protein translation by activating phosphatidylinositol 3 kinase/mTOR.

Sokolova O, Vieth M, Gnad T, Bozko PM, Naumann M.

Int J Biochem Cell Biol. 2014 Oct;55:157-63. doi: 10.1016/j.biocel.2014.08.023. Epub 2014 Sep 4.

14.

Editorial: Gut microbiota and gastrointestinal diseases: to treat or not to treat.

Bien J, Bozko M, Malek NP, Bozko P.

Curr Pharm Des. 2014;20(28):4533-4. No abstract available.

PMID:
24998646
15.

Editorial: Helicobacter pylori eradication therapy: advantages and disadvantages.

Bien J, Bozko M, Malek NP, Bozko P.

Curr Pharm Des. 2014;20(28):4487-8. No abstract available.

PMID:
24998645
16.

Capsaicin treatment attenuates cholangiocarcinoma carcinogenesis.

Wutka A, Palagani V, Barat S, Chen X, El Khatib M, Götze J, Belahmer H, Zender S, Bozko P, Malek NP, Plentz RR.

PLoS One. 2014 Apr 18;9(4):e95605. doi: 10.1371/journal.pone.0095605. eCollection 2014. Erratum in: PLoS One. 2016;11(9):e0162673.

17.

Baceridin, a cyclic hexapeptide from an epiphytic bacillus strain, inhibits the proteasome.

Niggemann J, Bozko P, Bruns N, Wodtke A, Gieseler MT, Thomas K, Jahns C, Nimtz M, Reupke I, Brüser T, Auling G, Malek N, Kalesse M.

Chembiochem. 2014 May 5;15(7):1021-9. doi: 10.1002/cbic.201300778. Epub 2014 Apr 1.

PMID:
24692199
18.

Combined inhibition of Notch and JAK/STAT is superior to monotherapies and impairs pancreatic cancer progression.

Palagani V, Bozko P, El Khatib M, Belahmer H, Giese N, Sipos B, Malek NP, Plentz RR.

Carcinogenesis. 2014 Apr;35(4):859-66. doi: 10.1093/carcin/bgt394. Epub 2013 Nov 30.

PMID:
24293409
19.

Activation of Notch signaling is required for cholangiocarcinoma progression and is enhanced by inactivation of p53 in vivo.

El Khatib M, Bozko P, Palagani V, Malek NP, Wilkens L, Plentz RR.

PLoS One. 2013 Oct 30;8(10):e77433. doi: 10.1371/journal.pone.0077433. eCollection 2013. Erratum in: PLoS One. 2018 Nov 1;13(11):e0206953.

20.

Editorial: Gut Microbiota and Gastrointestinal Diseases: to Treat or Not To Treat.

Bien J, Bozko M, P Malek N, Bozko P.

Curr Pharm Des. 2013 Oct 14. [Epub ahead of print] No abstract available.

PMID:
24180401
21.

A critical role for notch signaling in the formation of cholangiocellular carcinomas.

Zender S, Nickeleit I, Wuestefeld T, Sörensen I, Dauch D, Bozko P, El-Khatib M, Geffers R, Bektas H, Manns MP, Gossler A, Wilkens L, Plentz R, Zender L, Malek NP.

Cancer Cell. 2013 Jun 10;23(6):784-95. doi: 10.1016/j.ccr.2013.04.019. Epub 2013 May 30. Erratum in: Cancer Cell. 2016 Aug 8;30(2):353-356.

22.

The intestinal microbiota dysbiosis and Clostridium difficile infection: is there a relationship with inflammatory bowel disease?

Bien J, Palagani V, Bozko P.

Therap Adv Gastroenterol. 2013 Jan;6(1):53-68. doi: 10.1177/1756283X12454590.

23.

Epithelial mesenchymal transition and pancreatic tumor initiating CD44+/EpCAM+ cells are inhibited by γ-secretase inhibitor IX.

Palagani V, El Khatib M, Kossatz U, Bozko P, Müller MR, Manns MP, Krech T, Malek NP, Plentz RR.

PLoS One. 2012;7(10):e46514. doi: 10.1371/journal.pone.0046514. Epub 2012 Oct 19.

24.

Editorial: the importance of rational chemotherapy of chronic lymphocytic leukemia.

Podhorecka M, Bozko P.

Curr Pharm Des. 2012;18(23):3321-2. No abstract available.

PMID:
22591388
25.

Role of Uropathogenic Escherichia coli Virulence Factors in Development of Urinary Tract Infection and Kidney Damage.

Bien J, Sokolova O, Bozko P.

Int J Nephrol. 2012;2012:681473. doi: 10.1155/2012/681473. Epub 2012 Mar 8.

27.

H2AX Phosphorylation: Its Role in DNA Damage Response and Cancer Therapy.

Podhorecka M, Skladanowski A, Bozko P.

J Nucleic Acids. 2010 Aug 3;2010. pii: 920161. doi: 10.4061/2010/920161.

28.

Helicobacter pylori induces NF-kappaB independent of CagA.

Schweitzer K, Sokolova O, Bozko PM, Naumann M.

EMBO Rep. 2010 Jan;11(1):10-1; author reply 11-2. doi: 10.1038/embor.2009.263. No abstract available.

29.

DNA structure and integrity checkpoints during the cell cycle and their role in drug targeting and sensitivity of tumor cells to anticancer treatment.

Skladanowski A, Bozko P, Sabisz M.

Chem Rev. 2009 Jul;109(7):2951-73. doi: 10.1021/cr900026u. Review. No abstract available.

PMID:
19522503
30.

Helicobacter pylori suppresses glycogen synthase kinase 3beta to promote beta-catenin activity.

Sokolova O, Bozko PM, Naumann M.

J Biol Chem. 2008 Oct 24;283(43):29367-74. doi: 10.1074/jbc.M801818200. Epub 2008 Sep 4.

31.

The influence of G(2) arrest abrogation on the long-term cytotoxicity of different genotoxic lesions.

Bozko P, Larsen AK, Skladanowski A.

Cell Cycle. 2008 Jun 15;7(12):1880-3. Epub 2008 Jun 7. No abstract available.

PMID:
18583927
32.

Dual inhibition of PI3K/Akt signaling and the DNA damage checkpoint in p53-deficient cells with strong survival signaling: implications for cancer therapy.

Skladanowski A, Bozko P, Sabisz M, Larsen AK.

Cell Cycle. 2007 Sep 15;6(18):2268-75. Epub 2007 Jul 5.

PMID:
17890906
33.

CSN controls NF-kappaB by deubiquitinylation of IkappaBalpha.

Schweitzer K, Bozko PM, Dubiel W, Naumann M.

EMBO J. 2007 Mar 21;26(6):1532-41. Epub 2007 Feb 22.

34.

Specific role of the SR protein splicing factor B52 in cell cycle control in Drosophila.

Rasheva VI, Knight D, Bozko P, Marsh K, Frolov MV.

Mol Cell Biol. 2006 May;26(9):3468-77.

35.

Cross-talk between DNA damage and cell survival checkpoints during G2 and mitosis: pharmacologic implications.

Bozko P, Sabisz M, Larsen AK, Skladanowski A.

Mol Cancer Ther. 2005 Dec;4(12):2016-25.

36.

Antitumour imidazoacridone C-1311 induces cell death by mitotic catastrophe in human colon carcinoma cells.

Hyzy M, Bozko P, Konopa J, Skladanowski A.

Biochem Pharmacol. 2005 Mar 1;69(5):801-9. Epub 2005 Jan 18.

PMID:
15710357
37.

Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors.

Issaeva N, Bozko P, Enge M, Protopopova M, Verhoef LG, Masucci M, Pramanik A, Selivanova G.

Nat Med. 2004 Dec;10(12):1321-8. Epub 2004 Nov 21.

PMID:
15558054
38.

Rescue of mutants of the tumor suppressor p53 in cancer cells by a designed peptide.

Issaeva N, Friedler A, Bozko P, Wiman KG, Fersht AR, Selivanova G.

Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13303-7. Epub 2003 Oct 31.

39.

Supplemental Content

Support Center